Computer-aided detection (CAD) firm iCAD has signed a definitive agreement to acquire the principal assets of MRI CAD developer CAD Sciences.
iCAD will pay $2 million in cash and $3 million in shares of its common stock for the White Plains, NY-based firm. The deal will extend iCAD's product and technology portfolio and provide for the application of kinetics technology for the breast and prostate, according to the Nashua, NH-based vendor.
CAD Sciences also is developing products for therapy monitoring, identification of vascular diseases using contrast-enhanced MR angiography, and cancer detection using contrast-enhanced CT, iCAD said. The deal is expected to close early in the third quarter of 2008, subject to certain conditions.
Related Reading
iCAD launches clinical study for colon CAD, June 19, 2008
iCAD trims net loss, May 7, 2008
FDA OKs iCAD SecondLook with Fuji FCRm, April 7, 2008
iCAD nets CAD patent, April 1, 2008
Road to RSNA, CAD, CAD Sciences, November 3, 2006
Copyright © 2008 AuntMinnie.com
